
Opinion|Videos|March 6, 2025
PEACE-3 Study Results: Safety
Author(s)Abhishek Tripathi, MD
An expert discusses the safety findings from the PEACE-3 study, highlighting the adverse events associated with the combination of enzalutamide and radium-223 in ARPI-naïve metastatic castration-resistant prostate cancer.
Advertisement
Episodes in this series

What about the safety findings?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
3
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
4
New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches
5



















